{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:03:24Z","timestamp":1774080204147,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No evidence of disease activity-3 (NEDA-3) constitutes a crucial target for relapsing-remitting multiple sclerosis (RRMS). Long-term predictors of its attainment remain insufficiently characterized. This study aimed to assess the prevalence and the predictors of long-term NEDA-3 status in a large real-world RRMS cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective monocentric study analyzed RRMS patients strictly followed for up to six years. Treatment exposure was classified based on the efficacy of the first therapy in moderate (ME) and high efficacy (HE) disease modifying treatments (DMTs). Percentages of patients exposed to ME and HE DMTs reaching NEDA-3 were compared. Logistic regression models were applied to identify predictors of NEDA-3 achievement at 2 and 5 years. EBNA-1 IgG and VCA IgG from Epstein-Barr virus (EBV) were also analyzed in a small sub-cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>485 RRMS patients were included. Subjects starting treatment with HE DMTs were associated with significantly higher rates of NEDA-3 across all time-points. Significant risk factors for not achieving NEDA-3 included multifocal onset, delayed treatment initiation and spinal cord lesions. Conversely, treatment initiation with HE DMT was a significant protective factor for NEDA-3 status achievement at 2 and 5 years of follow-up. Early initiation of HE DMTs significantly improves long-term control of disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multifocal onset, delayed treatment initiation, presence of spinal cord lesions and oligoclonal bands were identified as risk factors of not achieving NEDA-3 status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-08876-x","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T02:27:21Z","timestamp":1770863241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world data"],"prefix":"10.1007","volume":"47","author":[{"given":"Tommaso","family":"Guerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Esposto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Intini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Amati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Guglielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-1731","authenticated-orcid":false,"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"9","key":"8876_CR1","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u20133161","journal-title":"Brain"},{"issue":"9","key":"8876_CR2","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdov\u00e1 E (2017) \u201fNo evident disease activity: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179\u20131187","journal-title":"Mult Scler"},{"issue":"6","key":"8876_CR3","doi-asserted-by":"publisher","first-page":"e1059","DOI":"10.1212\/NXI.0000000000001059","volume":"8","author":"L Prosperini","year":"2021","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Pozzilli C, Gasperini C (2021) Prognostic accuracy of NEDA-3 in Long-term outcomes of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8(6):e1059 PMID: 34373345; PMCID: PMC8353667","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8876_CR4","doi-asserted-by":"publisher","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152-8. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537","DOI":"10.1001\/jamaneurol.2014.3537"},{"issue":"9","key":"8876_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/ene.13669","volume":"25","author":"H Hegen","year":"2018","unstructured":"Hegen H, Bsteh G, Berger T (2018) \u201fNo evidence of disease activity\u2013is it an appropriate surrogate in multiple sclerosis? Eur J Neurol 25(9):1107\u2013e101","journal-title":"Eur J Neurol"},{"key":"8876_CR6","doi-asserted-by":"crossref","unstructured":"Gross RH, Corboy JR (2019) Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies [published correction appears in Continuum (Minneap Minn). 2019;25(4):1175]. Continuum (Minneap Minn) 25(3):715\u2013735","DOI":"10.1212\/CON.0000000000000738"},{"issue":"3","key":"8876_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00415-023-12137-8","volume":"271","author":"P Iaffaldano","year":"2024","unstructured":"Iaffaldano P, Lucisano G, Guerra T et al (2024) Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS registry. J Neurol 271(3):1150\u20131159","journal-title":"J Neurol"},{"issue":"3","key":"8876_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/ijms26030884","volume":"26","author":"T Guerra","year":"2025","unstructured":"Guerra T, Iaffaldano P (2025) A window into new insights on progression independent of relapse activity in multiple sclerosis: role of therapies and current perspective. Int J Mol Sci 26(3):884 Published 2025 Jan 21. https:\/\/doi.org\/10.3390\/ijms26030884","journal-title":"Int J Mol Sci"},{"key":"8876_CR9","doi-asserted-by":"crossref","unstructured":"Filippi M, Amato MP, Centonze D et al (2022) Early use of high-efficacy disease\u2013modifying therapies makes the difference in people with multiple sclerosis: an expert opinion [published correction appears in J Neurol 269(12):6690\u20136691. doi: 10.1007\/s00415-022-11385-4]. J Neurol 269(10):5382\u20135394","DOI":"10.1007\/s00415-022-11193-w"},{"key":"8876_CR10","doi-asserted-by":"publisher","first-page":"693017","DOI":"10.3389\/fneur.2021.693017","volume":"12","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen H\u00d8, Broch L et al (2021) Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian Population-Based registry. Front Neurol 12:693017 Published 2021 Jun 17","journal-title":"Front Neurol"},{"key":"8876_CR11","doi-asserted-by":"publisher","first-page":"105594","DOI":"10.1016\/j.msard.2024.105594","volume":"87","author":"E Signoriello","year":"2024","unstructured":"Signoriello E, Signori A, Lus G et al (2024) NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or natalizumab. Mult Scler Relat Disord 87:105594. https:\/\/doi.org\/10.1016\/j.msard.2024.105594","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"8876_CR12","doi-asserted-by":"publisher","first-page":"e200032","DOI":"10.1212\/NXI.0000000000200032","volume":"9","author":"D Rotstein","year":"2022","unstructured":"Rotstein D, Solomon JM, Sormani MP et al (2022) Association of NEDA-4 with no Long-term disability progression in multiple sclerosis and comparison with NEDA-3: A systematic review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm 9(6):e200032 Published 2022 Oct 12","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"8876_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WCO.0000000000001057","volume":"35","author":"M Trojano","year":"2022","unstructured":"Trojano M, Kalincik T, Iaffaldano P, Amato MP (2022) Interrogating large multiple sclerosis registries and databases: what information can be gained? Curr Opin Neurol 35(3):271\u2013277. https:\/\/doi.org\/10.1097\/WCO.0000000000001057","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"8876_CR14","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s10072-023-06876-9","volume":"44","author":"P Mosconi","year":"2023","unstructured":"Mosconi P, Guerra T, Paletta P et al (2023) Data monitoring roadmap. The experience of the Italian multiple sclerosis and related disorders register. Neurol Sci 44(11):4001\u20134011. https:\/\/doi.org\/10.1007\/s10072-023-06876-9","journal-title":"Neurol Sci"},{"key":"8876_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4:329\u2013333","journal-title":"Mult Scler Relat Disord"},{"key":"8876_CR16","doi-asserted-by":"publisher","first-page":"116827","DOI":"10.1016\/j.jns.2020.116827","volume":"414","author":"E Tsantes","year":"2020","unstructured":"Tsantes E, Curti E, Collura F, Bazzurri V, Fiore A, Granella F (2020) Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. J Neurol Sci 414:116827. https:\/\/doi.org\/10.1016\/j.jns.2020.116827","journal-title":"J Neurol Sci"},{"issue":"4","key":"8876_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00415-023-12021-5","volume":"271","author":"D Ontaneda","year":"2024","unstructured":"Ontaneda D, Chitnis T, Rammohan K, Obeidat AZ (2024) Identification and management of subclinical disease activity in early multiple sclerosis: a review. J Neurol 271(4):1497\u20131514","journal-title":"J Neurol"},{"issue":"6","key":"8876_CR18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","volume":"12","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J (2023) No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]. Neurol Ther 12(6):1909\u20131935","journal-title":"Neurol Ther"},{"issue":"1","key":"8876_CR19","first-page":"205521732311547","volume":"9","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L et al (2023) Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Mult Scler J Exp Transl Clin 9(1):20552173231154712 Published 2023 Feb 22","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"8876_CR20","first-page":"205521731876064","volume":"4","author":"E Havrdov\u00e1","year":"2018","unstructured":"Havrdov\u00e1 E, Arnold DL, Bar-Or A et al (2018) No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with Ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin 4(1):2055217318760642 Published 2018 Mar 12","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11","key":"8876_CR21","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1007\/s10072-021-05127-z","volume":"42","author":"T Guerra","year":"2021","unstructured":"Guerra T, Caputo F, Orlando B, Paolicelli D, Trojano M, Iaffaldano P (2021) Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and Fingolimod for up to 4 years. Neurol Sci 42(11):4647\u20134655","journal-title":"Neurol Sci"},{"key":"8876_CR22","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.msard.2020.102543","volume":"46","author":"D Horakova","year":"2020","unstructured":"Horakova D, Uher T, Krasensky J et al (2020) Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Mult Scler Relat Disord 46:102543","journal-title":"Mult Scler Relat Disord"},{"key":"8876_CR23","doi-asserted-by":"crossref","unstructured":"Zanetta C, Rocca MA, Meani A et al (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study [published correction appears in J Neurol 270(7):3565\u20133566. doi: 10.1007\/s00415-023-11772-5]. J Neurol 270(7):3553\u20133564","DOI":"10.1007\/s00415-023-11700-7"},{"issue":"1","key":"8876_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","volume":"32","author":"B Weinstock-Guttman","year":"2018","unstructured":"Weinstock-Guttman B, Medin J, Khan N et al (2018) Assessing \u2018No evidence of disease activity\u2019 status in patients with Relapsing-Remitting multiple sclerosis receiving Fingolimod in routine clinical practice: A retrospective analysis of the multiple sclerosis clinical and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. CNS Drugs 32(1):75\u201384","journal-title":"CNS Drugs"},{"issue":"4","key":"8876_CR25","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00415-023-12021-5","volume":"271","author":"D Ontaneda","year":"2024","unstructured":"Ontaneda D, Chitnis T, Rammohan K, Obeidat AZ (2024) Identification and management of subclinical disease activity in early multiple sclerosis: a review. J Neurol 271(4):1497\u20131514. https:\/\/doi.org\/10.1007\/s00415-023-12021-5","journal-title":"J Neurol"},{"key":"8876_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.12688\/f1000research.11349.1","volume":"6","author":"C Ana","year":"2017","unstructured":"LONDO\u00d1O, Ana C, MORA, Carlos A (2017) Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis. F1000Research 6:566","journal-title":"F1000Research"},{"key":"8876_CR27","doi-asserted-by":"crossref","unstructured":"Iaffaldano P, Portaccio E, Lucisano G et al (2024) Multiple sclerosis progression and relapse activity in children [published correction appears in JAMA Neurol 81(1):88. doi: 10.1001\/jamaneurol.2023.5461]. JAMA Neurol 81(1):50\u201358","DOI":"10.1001\/jamaneurol.2023.5461"},{"issue":"4","key":"8876_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316","journal-title":"Lancet Neurol"},{"issue":"8","key":"8876_CR29","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/brain\/awz156","volume":"142","author":"WJ Brownlee","year":"2019","unstructured":"Brownlee WJ, Altmann DR, Prados F et al (2019) Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142(8):2276\u20132287","journal-title":"Brain"},{"issue":"3","key":"8876_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1352458520974366","volume":"27","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Patti F et al (2021) Transition to secondary progression in relapsing-onset multiple sclerosis: definitions and risk factors. Mult Scler 27(3):430\u2013438","journal-title":"Mult Scler"},{"issue":"10","key":"8876_CR31","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.3390\/ijms25105412","volume":"25","author":"G Maglio","year":"2024","unstructured":"Maglio G, D\u2019Agostino M, Caronte FP et al (2024) Multiple sclerosis: from the application of oligoclonal bands to novel potential biomarkers. Int J Mol Sci 25(10):5412 Published 2024 May 15. https:\/\/doi.org\/10.3390\/ijms25105412","journal-title":"Int J Mol Sci"},{"key":"8876_CR32","doi-asserted-by":"publisher","first-page":"105037","DOI":"10.1016\/j.msard.2023.105037","volume":"79","author":"BE R\u00f8d","year":"2023","unstructured":"R\u00f8d BE, Wergeland S, Bj\u00f8rnevik K et al (2023) Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. Mult Scler Relat Disord 79:105037. https:\/\/doi.org\/10.1016\/j.msard.2023.105037","journal-title":"Mult Scler Relat Disord"},{"issue":"6578","key":"8876_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC et al (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375(6578):296\u2013301. https:\/\/doi.org\/10.1126\/science.abj8222","journal-title":"Science"},{"issue":"20","key":"8876_CR34","doi-asserted-by":"publisher","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","volume":"9","author":"OG Thomas","year":"2023","unstructured":"Thomas OG, Bronge M, Tengvall K et al (2023) Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci Adv 9(20):eadg3032. https:\/\/doi.org\/10.1126\/sciadv.adg3032","journal-title":"Sci Adv"},{"key":"8876_CR35","doi-asserted-by":"publisher","first-page":"991662","DOI":"10.3389\/fimmu.2022.991662","volume":"13","author":"MI Dom\u00ednguez-Mozo","year":"2022","unstructured":"Dom\u00ednguez-Mozo MI, L\u00f3pez-Lozano L, P\u00e9rez-P\u00e9rez S et al (2022) Epstein-Barr virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study. Front Immunol 13:991662 Published 2022 Sep 14","journal-title":"Front Immunol"},{"key":"8876_CR36","doi-asserted-by":"publisher","first-page":"1384411","DOI":"10.3389\/fimmu.2024.1384411","volume":"15","author":"MI Dominguez-Mozo","year":"2024","unstructured":"Dominguez-Mozo MI, Gal\u00e1n V, Rami\u00f3-Torrent\u00e0 L et al (2024) A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression. Front Immunol 15:1384411 Published 2024 Jun 7. https:\/\/doi.org\/10.3389\/fimmu.2024.1384411","journal-title":"Front Immunol"},{"key":"8876_CR37","doi-asserted-by":"publisher","first-page":"1259306","DOI":"10.3389\/fnins.2023.1259306","volume":"17","author":"F Palavra","year":"2023","unstructured":"Palavra F, Silva D, Fernandes C et al (2023) Clinical predictors of NEDA-3 one year after diagnosis of pediatric multiple sclerosis: an exploratory single-center study. Front Neurosci 17:1259306. https:\/\/doi.org\/10.3389\/fnins.2023.1259306. Published 2023 Sep 14","journal-title":"Front Neurosci"},{"issue":"8","key":"8876_CR38","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1177\/13524585211049392","volume":"28","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P (2022) Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler 28(8):1219\u20131228","journal-title":"Mult Scler"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08876-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08876-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:36:31Z","timestamp":1774074991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08876-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["8876"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08876-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest with respect to the contents of the current study, but note that the patients in the study were treated with a number of disease-modifying drugs and that authors have received advisory board, membership, speakers honoraria, travel support, research grants, consulting fees, or clinical trial support from the manufacturers of those drugs, including Actelion, Allergan, Almirall, Alexion, Bayer Schering, Biogen, Bristol-Myers Squibb, Celgene, Excemed, Genzyme, Forward Pharma, Ipsen, Medday, Merck, Mylan, Novartis, Sanofi, Roche, Teva, and their local affiliates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data about the cohort considered in the study were collected from the database of the Italian Multiple Sclerosis Register (RISM), of which our centre is a part. RISM was approved by the ethical committee at the \u201cAzienda Ospedaliera\/Universitaria\u2014Policlinico of Bari\u201d (Study REGISTRO SM001, approved on 08\/07\/2016). Patients signed an informed consent that allows to use clinical data for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"251"}}